Initial target indications are in fertility and pregnancy, where the company seeks to offer the world’s first drug-device combo product to help prevent miscarriages and for IVF luteal support.
In time, this vaginal drug-delivery platform can be used to deliver a wide range of existing and upcoming vaginal therapeutics, including infertility, miscarriage, endometriosis, bacterial vaginosis and cervical cancer.
Sector: MedTech
Raise: £1.5m EIS eligible
PACP Partner Contact: Sharon O’Connor
Latest News
-
December Update – Current Investment Opportunities
Welcome to our December Update! Our final newsletter of 2024 gives updates on a selection of current investment opportunities with founder clients, at Seed to Series A stage. Please contact the PACP partner highlighted for further details, to request an investor deck and to arrange to meet directly with the founders Included in our update …
Continue reading “December Update – Current Investment Opportunities”
-
Christmas Gifts – Discounts With Our Founder Clients
As a Christmas gift from us, a selection of our Consumer clients have kindly offered discounts to use when purchasing online or instore: Saida’s Kitchen – Bringing the heart of East Africa to your table. 15% coupon code –SAIDA15OFF Valid until 28/2/25, one use per customer, no minimum spend Sign Of The Times …
Continue reading “Christmas Gifts – Discounts With Our Founder Clients”
-
Investment Opportunities – Sustainability Round Up
As COP29 ends, global leaders have announced their latest planned actions on tackling climate change. This will include more funding for climate action, stronger climate promises, shifting to clean energy and preparing for climate impacts. These actions are all aimed at building a sustainable future, focussing on the COP29 theme of ‘investing in a liveable …
Continue reading “Investment Opportunities – Sustainability Round Up”